KKLIU Approval for Meta Ads in Malaysia

The short answer

KKLIU is the approval reference the Ministry of Health stamps on an advertisement it has cleared for a medicine or a health service. It is issued by the Medicine Advertisements Board, known in Malay as the Lembaga Iklan Ubat, which exists because section 7(a) of the Medicines (Advertisement and Sale) Act 1956 empowers the Minister to make regulations establishing it for the purposes of sections 4A and 4B of that Act. If your Facebook or Instagram ad makes a medicinal or health-benefit claim to Malaysians, you generally need that approval before the ad runs, and the KKLIU number has to appear on the creative itself. For one set of conditions, covered further down, the Act does not offer an approval route at all.

Two things trip advertisers up. First, having a product registration number is not the same as having advertising approval; those are separate processes run by different parts of the system. Second, clearing the Malaysian requirement does not clear Meta's own rules, which independently restrict how you can advertise drugs, supplements and weight-loss products. A compliant health ad in Malaysia has to pass both gates. This article walks through each one, flags where the public information is thin, and points you to the authorities to confirm the details that matter most.

What KKLIU actually is

The Medicine Advertisements Board is the body inside the Ministry of Health that vets advertising for medicines and health services. Its legal footing is section 7(a) of the Medicines (Advertisement and Sale) Act 1956, Act 290, which lets the Minister make regulations that, for the purposes of sections 4A and 4B, establish the Medicine Advertisements Board. Those two sections then name the Board directly as the body whose approval an advertisement needs, and the rest of section 7 covers the manner of submission, fees, the Board's procedure and appeal to the Minister. Secondary summaries commonly date the establishing regulations to 1976 and attach a P.U.(A) number to them, but the subsidiary legislation for Act 290 is not retrievable from the Attorney General's Chambers portal, so we are not repeating that citation as settled fact. When the Board approves an advertisement, it issues an approval number in the format "KKLIU serial number/year", for example KKLIU 0213/2013, and that number must be displayed on every published version of the ad.

You will see the acronym KKLIU expanded in various ways online, usually along the lines of a Ministry of Health approval for a medicine advertisement. We could not confirm the exact official expansion verbatim from a loaded Ministry page in preparing this guide, so we are treating the acronym as the approval reference itself rather than quoting a precise wording. What matters operationally is simpler: KKLIU is the marker that an ad has been through the Board and been cleared, and its absence on a health-claim ad is a red flag both to regulators and to platforms.

Approval attaches to a specific creative. The Board reviews the actual visuals and wording you submit, so the number it issues belongs to that exact advertisement. Change the images or rewrite the claims and the original approval may no longer cover you.

Registration and advertising approval are two different things

This is the single most common misunderstanding, so it is worth slowing down on. Product registration and advertising approval answer different questions and are handled by different parts of the Ministry.

Registration is about the product. Under the Drug Control Authority, administered through NPRA, a medicine or health supplement is assessed for quality, safety and efficacy and, if it passes, is given a registration number. Cosmetics take a lighter route: they are notified to NPRA rather than registered as medicines, under the Control of Drugs and Cosmetics Regulations 1984. Advertising approval is about a particular advertisement, and that is the Medicine Advertisements Board's job. An approved medicine advertisement must carry the product's Drug Control Authority registration number as well as its KKLIU approval number.

The practical takeaway: a registration number lets you sell, a KKLIU number lets you advertise a given creative. Holding the first does not grant the second. Plenty of Malaysian sellers assume that because their supplement is registered, any ad they write is automatically fine. It is not.

The two-track system also explains a pattern the authorities see often: a genuinely registered product paired with an advertisement the Board never reviewed. Registration status can be checked by consumers against the authority's records, but that only tells them the product is legitimate, not that the specific claims in your ad were cleared. So even a fully registered supplement can generate a non-compliant ad the moment its creative reaches beyond the approved wording. The safeguard is to treat every new claim as a fresh advertising question, separate from whatever registration you already hold.

Which ads need Medicine Advertisements Board approval

The rule of thumb is that advertising touching medicines or health services needs approval before it is published, and Act 290 splits that into two sections doing two different jobs. Section 4B is the approval gate: no person shall publish an advertisement for the use of an article as a medicine, an appliance or a remedy for the treatment or prevention of diseases or conditions other than those specified in section 3(1), unless the Medicine Advertisements Board has approved it. Section 4A is the parallel provision for advertisements that refer to a skill or service for treating, preventing or diagnosing an ailment and are capable of inducing, or contain an express or implied invitation to, a person to seek the advertiser's advice, which is the section aesthetic clinics and medical laboratories run into. Guidance on the rules is explicit that materials making health claims, even implied ones, that target Malaysian consumers need KKLIU approval, and that this includes social-media posts, in-store displays, packaging stickers and advertising across all media.

Section 3(1) of the same Act is the other tier, and it is not a gate at all. It prohibits taking any part in publishing an advertisement calculated to lead to the use of an article as a medicine, an appliance or a remedy for preventing or treating the conditions in the Schedule to the Act, or for diagnosing them, or for the purpose of practising contraception, or for improving the condition or functioning of the human kidney or heart or improving the sexual function or sexual performance of human beings. The Schedule holds exactly twenty items: diseases or defects of the kidney; diseases or defects of the heart; diabetes; epilepsy or fits; paralysis; tuberculosis; asthma; leprosy; cancer; deafness; drug addiction; hernia or rupture; diseases of the eye; hypertension; mental disorder; infertility; frigidity; impairment of sexual function or impotency; venereal disease; and nervous debility or other complaint or infirmity arising from or relating to sexual intercourse. For any of those, "we will just apply for KKLIU" is not a plan, because the section 4B approval route is expressly limited to conditions outside section 3(1). The proviso to section 3 exempts publication by the Federal or a State Government, a local or public authority, the governing body of a public hospital, or a person the Minister has authorised, which is not a door a supplement brand walks through. So the architecture is two-tier: section 3 is an outright ban for the scheduled conditions, and section 4B is everything else, where everything else needs the Board's approval first.

One point on format, because it gets stated too strongly. Act 290 itself never uses the words internet, online, website, social media or electronic. Its definition of advertisement in section 2 reaches them through general words instead, covering any notice, circular, report, commentary, pamphlet, label, wrapper or other document, and any announcement made orally or by any means of producing or transmitting light or sound. The document that spells the digital formats out is the Board's own guideline on advertising medicines and medicinal products to the general public, which lists online advertising and website and other internet materials including brand home pages and banner advertising among the things it treats as advertisements, and closes with "and any other form or means of advertising". That guideline sits on a weaker footing than the Act: the Ministry host that should serve it did not respond on any attempt we made, and our copy came from a third-party mirror, so treat it as strong practice guidance rather than as text to quote at a regulator. Either way, a boosted Instagram post is an advertisement in exactly the same way a magazine page is.

The following matrix is a starting point, not a substitute for checking your specific product and claim with the authority.

It helps to be generous about what counts as an advertisement here. Because the guidance sweeps in health claims across all media, a boosted post, a paid influencer mention, an affiliate's caption and a live-selling session that promises a health benefit are all advertising in the eyes of the Board, not casual conversation. If you pay someone to put a medicinal or health-benefit claim in front of Malaysians, the approval obligation follows the claim rather than the format. That is easy to forget when the ad looks like an organic Reel or a candid testimonial video, yet the substance of the message is exactly what the rule cares about, and a native-looking post earns no special exemption.

Where the honest answer is "it depends on the exact wording," that is a signal to get the copy checked rather than to guess. Ads in health and beauty are among the most likely to be flagged, so claim discipline matters more here than in almost any other category.

Medicines, supplements and cosmetics are not the same lane

Because the approval requirement hinges on the claim and the product category, mixing the two is where advertisers get into trouble. A cosmetic that is notified to NPRA cannot lawfully make medicinal or treatment claims; the moment it does, it is being advertised as a medicine, which would require a medicine registration and Board clearance. So a moisturiser can talk about hydration and radiance, but "clears eczema" or "treats acne" pushes it into medicine territory.

The claims also have to match the product's approved category and evidence. Claims are supposed to be substantiable against approved labelling or scientific evidence, not aspirational marketing language. A supplement registered on one basis cannot suddenly claim to do something outside that basis just because it sounds better in an ad. If it helps to see where the line falls in practice, the archive sets of Malaysian supplement ads and cosmetics ads show the claim wording advertisers in each lane actually run.

A note on the registration-number formats: you will see references online to a "MAL" prefix for registered medicines and supplements and a "NOT" prefix for notified cosmetics. We saw those described in secondary summaries but could not confirm the precise digit-and-letter structure from a loaded NPRA page for this guide, so we are not stating the exact format as fact. If you need to verify a product's status or the correct number format, check directly with NPRA rather than relying on a marketing blog. The same discipline that keeps you inside halal ad creative rules applies here: match the claim to what the product is actually certified or registered to do.

What the KKLIU number looks like and where it goes

Once the Board approves an advertisement, the KKLIU number is not optional decoration. It must be displayed on every published version of that advertisement, and the format is "KKLIU serial number/year", such as KKLIU 0213/2013. The Board's guideline has a clause aimed squarely at digital that most Malaysian advertisers have never read: the KKLIU number must be clearly displayed on every page approved by the Board, and the name, address and contact number of the advertiser must also be clearly stated on the page. Pages aimed at health professionals rather than the public, it adds, must be access restricted and clearly labelled as intended for health professionals. That is guideline text rather than statute, and our copy of the guideline came from a third-party mirror rather than an official Ministry host, so confirm the advertiser-details line with the Board before you build it into a template. On a static Facebook image or an Instagram Story, the practical reading is to place the number somewhere legible within the creative or the caption. On a video, it should be visible in-frame long enough to be read. The Ministry's own guidance on how to recognise an approved advertisement is worth reading precisely because consumers are told to look for that number, which means its absence is conspicuous.

Because the approval is tied to the specific creative, treat the number as belonging to that exact ad. If you redesign the visuals, swap the hero image, or reword the claim, the original approval may no longer apply, and running the changed ad under the old number is not a safe assumption. Build a habit of tracking which KKLIU number maps to which live creative, especially if you run several variations. That mapping also helps if an ad is questioned: you can show the exact approved version. Keeping research, creative variants and their approvals organised in one place, whether in a spreadsheet or a platform like AdPlay.ai, saves a scramble later.

Meta's rules stack on top of the local ones

Clearing the Malaysian side does not clear Meta. Its advertising standards apply globally and independently, and for health-related products they are strict. For prescription drugs, Meta requires prior written authorization and limits those ads to the United States, Canada and New Zealand. Malaysia is not on that list, so there is effectively no compliant path to advertise prescription drugs to Malaysians on Facebook or Instagram, regardless of any local approval. Over-the-counter medicines are treated more leniently: Meta allows them where they comply with applicable local laws and where the audience is aged 18 or over. For Malaysia, "applicable local laws" is exactly the Medicines (Advertisement and Sale) Act 1956 and the KKLIU requirement.

It is worth being concrete about the over-the-counter path, because that is where most Malaysian health advertisers actually operate. Meta permits OTC medicine ads only where they follow applicable local laws and target an audience aged 18 or over, so age-gating your targeting is not optional. Layer the local requirement on top and the checklist is clear: the product must be lawfully sold, any health claim must carry KKLIU approval, the number must sit on the creative, and the audience must exclude under-18s. Miss the age setting and Meta can reject the ad on its own terms even when your Malaysian paperwork is perfect, which is a common and easily avoided stumble.

It is important to be precise about who requires what. Meta's published policies do not mention Malaysia or KKLIU at all, and there is no known field in Ads Manager to enter a KKLIU number. The obligation to hold approval and display the number is a Malaysian legal one that you must satisfy as the advertiser; Meta simply enforces its own separate rules. So do not tell yourself that passing Meta's review means you are compliant locally, and do not assume local approval will stop Meta from rejecting an ad that breaks its health standards. If your ad does get held up on Meta's side, that is Meta's own review process at work, separate from the KKLIU requirement.

The before-and-after and body-image trap

One Meta rule catches Malaysian health, beauty and fitness advertisers again and again: the ban on before-and-after imagery in weight-loss ads. Meta's Health and Wellness standard prohibits weight-loss ads that show side-by-side before-and-after comparisons of using a product or a transformation, with fitness classes as a stated exception. It also prohibits content that implies negative self-perception or promotes an ideal body type, requires that any results shown reflect realistic time-to-results, and requires 18-plus targeting for both weight-loss and cosmetic-procedure ads.

That means the split-screen slimming ad, a staple of local supplement marketing, is likely to be rejected on Meta even if every Malaysian approval is in order. The two rule sets are additive, not interchangeable. The fix is not to fight the policy but to build creative that never relied on it: show the product and how it fits a routine, use testimonials that avoid shaming language, and be honest about timelines. Formats that lead with the product and with honest social proof stay inside the rules while still doing the persuasive work. Weave the KKLIU number into that compliant creative and you have covered both gates at once.

The penalty for skipping approval

There is a real cost to advertising without approval. Section 5(1) of the Medicines (Advertisement and Sale) Act 1956 makes a contravention of section 3, 4, 4A or 4B punishable on summary conviction by a fine not exceeding RM3,000 or imprisonment not exceeding one year or both on a first conviction, and a fine not exceeding RM5,000 or imprisonment not exceeding two years or both on a subsequent conviction. Secondary reporting adds product seizure and blacklisting to the picture. The section is written around contraventions rather than campaigns, so a flight of several unapproved ads is not something to assume the law will treat as a single lapse.

Worth knowing if you ever cite section 5 of the Act, because published summaries of it contradict each other and the reason is in the text: section 5 does not have one section list, it has three. The penalty in section 5(1) reaches sections 3, 4, 4A and 4B. The presumption of participation in section 5(2) and the defences in section 5(3), including the defence for publications circulating mainly among registered medical practitioners, dentists, nurses and midwives, pharmacists and licensed poisons wholesalers and retailers, reach only sections 3, 4 and 4B. Section 4A is carved out and given its own equivalents at sections 5(2A) and 5(4). Quote either list as if it were the whole of section 5 and you are half right, which is the worse half.

Those amounts are strikingly low by modern standards, which is one reason enforcement also leans on product seizure, blacklisting and platform action rather than the fine alone. They are, however, current. Act A481 raised them to these figures with effect from 1 March 1980, the Attorney General's Chambers reprint of Act 290 as at 1 May 2013 still carries them, and the Chambers' own amendment record for the Act shows nothing amending it after 1990. So do not assume a larger modern number is hiding somewhere. What is not in doubt is the direction: running unapproved health ads exposes you to legal penalties on the Malaysian side and to rejection, removal and account action on Meta's side, which can escalate to a restricted or disabled account.

A practical sequence before you press publish

Putting it together, here is a sensible order of operations for a Malaysian health, supplement or skincare advertiser preparing a Meta campaign. This is a general workflow, not legal advice, and the specifics of your product may change it.

First, confirm the product's status with NPRA. Is it a registered medicine or supplement, or a notified cosmetic? That determines what claims are even on the table. Second, if the ad makes any medicinal or health-benefit claim, seek Medicine Advertisements Board approval for the exact creative before you run it, not after. Third, put the KKLIU number, and the product registration number where required, visibly on the creative. Fourth, run the creative against Meta's own rules: no banned before-and-after, no content implying negative self-perception, realistic timelines, 18-plus targeting for weight-loss and cosmetic-procedure ads, and no attempt to advertise prescription drugs to a Malaysian audience.

Approval covers a specific creative, so bake this sequence into your production process rather than treating it as a one-off. Every genuinely new variation may need its own clearance. Building your ad testing plan around approved creatives from the start, as our guide on running a Facebook ad describes, is far cheaper than pulling live ads after a rejection.

What we could not verify, and why that matters

Being straight about the gaps is part of doing this responsibly, and the gaps have moved since this guide first went up. The turnaround time from submission to a decision and any application fees still vary between secondary sources, one quoting a few working days from a complete application and another several weeks plus a fee range, and none of them came from an official Ministry of Health page, so we are not stating a timeline or a fee. On validity we can now do better than the secondary guesses, which cluster around a year: the Board's own guideline says a certificate of approval is valid for three calendar years unless otherwise specified, that amendments to an approved advertisement must be requested within two months and are allowed once only, and that changes to pricing, company name, logo, address, contacts, layout and the approved URL can be notified without a fresh approval. Our copy of that guideline came from a third-party mirror rather than from the Ministry host, which did not respond on any attempt, so treat it as strong practice guidance and confirm the current version with the Board before you plan a launch around it.

Likewise, the precise registration-number formats, the official expansion of the KKLIU acronym and the gazette citation for the regulations that established the Board are things we saw only in secondary summaries and are not asserting as settled. What is well supported now sits in two clear tiers. From the Act itself, read against the Attorney General's Chambers reprints: the Board's legal basis in section 7(a), the section 4B approval requirement, the section 4A rule for skills and services, the outright section 3 ban for the twenty conditions in the Schedule, and the RM3,000 first-conviction and RM5,000 subsequent-conviction penalties in section 5(1). From the Board's guideline, which we could only read on a third-party mirror: the display of the KKLIU number on every approved page, the three-year validity, and the express treatment of online advertising as advertising. Meta's rules come from its own published standards. For anything beyond those, confirm with the Medicine Advertisements Board, NPRA or a licensed regulatory agent before you spend. Health advertising in Malaysia is one of the areas where a quick verification call is worth far more than the price of getting it wrong. This is educational content, not legal advice, and the governing law here is the Medicines (Advertisement and Sale) Act 1956, administered by the Ministry of Health.